藍帆醫療(002382.SZ):2021年度擬使用各種貨幣開展金融衍生品交易業務 金額不超10億元
格隆匯 12 月 4日丨藍帆醫療(002382.SZ)公佈,公司於2020年12月4日召開第五屆董事會第十次會議,公司審議通過了《關於公司及子公司2021年度開展金融衍生品交易的議案》,為有效的規避和防範匯率、利率波動風險,結合未來資本運作和日常經營需要,公司及子公司2021年度擬使用各種貨幣開展金融衍生品交易業務,金額不超過10億元。
公司及子公司開展金融衍生品的品種僅包括遠期結售匯、期權和互換,最長交割期限不超過12個月。公司董事會授權管理層在此額度範圍內根據業務情況、實際需要審批金融衍生品交易業務和選擇合作金融機構。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.